Literature DB >> 26545615

CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis.

Patrycja Koszałka1, Monika Gołuńska2, Marcin Stanisławowski3, Aleksandra Urban4, Grzegorz Stasiłojć5, Marceli Majewski6, Piotr Wierzbicki7, Andrzej C Składanowski8, Jacek Bigda9.   

Abstract

Ecto-5'-nucleotidase (CD73), an enzyme providing interstitial adenosine, mediates diverse physiological and pathological responses. In tumor progression, it has primarily an immunosuppressive role but is also thought to regulate neovascularization. However, the latter role is still in debate. When B16F10 melanoma was subcutaneously injected into CD73 knockout mice, changes in the tumor vasculature were not always observed. However, we demonstrated earlier that the growth and vascularization of B16F10 melanoma in CD73 knockout mice depend on the low presence of CD73 on tumor cells. To further analyze the role of CD73 on tumor growth and vascularization, we compared the changes in B16F10 melanoma subcutaneously injected into right flank of wild-type mice, CD73 knockout mice lacking host CD73 only, and CD73 knockout mice with tumor cell CD73 either inhibited with AOPCP (adenosine α,β-methylene 5'-diphosphate) or permanently knocked down through genetic modification. We report here that both inhibition and knockdown of tumor CD73 further inhibited tumor growth compared to host CD73 knockout alone. MAP-kinase signaling pathway activation also decreased more strongly in the stable knockdown. There was a significant reduction in the angiogenic activation of blood microvessels as observed by decreased anti-VEGFR2 staining. Stable CD73 knockdown also reduced endothelial cell proliferation as measured by anti-CD105 staining. However, only chemical inhibition with AOPCP significantly augmented the reduction in intratumoral microvessel density induced by host CD73 knockout. Such reduction was not observed when tumor CD73 was knocked down due to the much slower tumor growth and decreased oxygen demand as indicated by the low expression of Bad, a hypoxia marker. Decreased CD73 activity also led to the decreased expression of angiogenic factors, including VEGF and bFGF that was only partially reversed by hypoxia in tumors treated with AOPCP. Both inhibition and knockdown of tumor CD73 significantly decreased tumor macrophage infiltration and induced microenvironment changes, thereby influencing MI or MII macrophage polarization. Additionally, tumor cell CD73 is important in metastasis formation through adenosine-independent attachment to endothelium. We conclude that even low tumor cell CD73 expression has an undeniable role in melanoma progression, including the regulation of many aspects of angiogenesis. CD73 is thus a viable target in anti-angiogenic melanoma therapy.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  B16F10 melanoma; Ecto-5′-nucleotidase; Metastasis; Tumor macrophage infiltration; Tumor neovascularization and angiogenesis

Mesh:

Substances:

Year:  2015        PMID: 26545615     DOI: 10.1016/j.biocel.2015.10.003

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  15 in total

1.  Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.

Authors:  J H Azambuja; R S Schuh; L R Michels; N E Gelsleichter; L R Beckenkamp; I C Iser; G S Lenz; F H de Oliveira; G Venturin; S Greggio; J C daCosta; M R Wink; J Sevigny; M A Stefani; A M O Battastini; H F Teixeira; E Braganhol
Journal:  Mol Neurobiol       Date:  2019-08-12       Impact factor: 5.590

2.  CD73: an emerging checkpoint for cancer immunotherapy.

Authors:  Siqi Chen; Derek A Wainwright; Jennifer D Wu; Yong Wan; Daniela E Matei; Yi Zhang; Bin Zhang
Journal:  Immunotherapy       Date:  2019-06-21       Impact factor: 4.196

3.  Specific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage Infiltration.

Authors:  Patrycja Koszałka; Monika Gołuńska; Aleksandra Urban; Grzegorz Stasiłojć; Marcin Stanisławowski; Marceli Majewski; Andrzej C Składanowski; Jacek Bigda
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

4.  MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma.

Authors:  Nathalie Bonnin; Emma Armandy; Julien Carras; Sylvain Ferrandon; Priscillia Battiston-Montagne; Marc Aubry; Sébastien Guihard; David Meyronet; Jean-Philippe Foy; Pierre Saintigny; Sonia Ledrappier; Alain Jung; Ruth Rimokh; Claire Rodriguez-Lafrasse; Delphine Poncet
Journal:  Oncotarget       Date:  2016-07-12

Review 5.  Pro-tumor activities of macrophages in the progression of melanoma.

Authors:  Huafeng Wang; Luhong Yang; Dong Wang; Qi Zhang; Lijuan Zhang
Journal:  Hum Vaccin Immunother       Date:  2017-04-25       Impact factor: 3.452

6.  Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.

Authors:  Yusuke Inoue; Katsuhiro Yoshimura; Nobuya Kurabe; Tomoaki Kahyo; Akikazu Kawase; Masayuki Tanahashi; Hiroshi Ogawa; Naoki Inui; Kazuhito Funai; Kazuya Shinmura; Hiroshi Niwa; Takafumi Suda; Haruhiko Sugimura
Journal:  Oncotarget       Date:  2017-01-31

7.  CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity.

Authors:  Zhao-Wei Gao; Hui-Ping Wang; Fang Lin; Xi Wang; Min Long; Hui-Zhong Zhang; Ke Dong
Journal:  BMC Cancer       Date:  2017-02-15       Impact factor: 4.430

8.  CD73 expression and clinical significance in human metastatic melanoma.

Authors:  Inês Monteiro; Selena Vigano; Mohamed Faouzi; Isabelle Treilleux; Olivier Michielin; Christine Ménétrier-Caux; Christophe Caux; Pedro Romero; Laurence de Leval
Journal:  Oncotarget       Date:  2018-06-01

Review 9.  Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.

Authors:  Simone de Leve; Florian Wirsdörfer; Verena Jendrossek
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

Review 10.  Targeting CD73 to augment cancer immunotherapy.

Authors:  Meejeon Roh; Derek A Wainwright; Jennifer D Wu; Yong Wan; Bin Zhang
Journal:  Curr Opin Pharmacol       Date:  2020-08-07       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.